Adenoviruses in oncology: A viable option?

BioDrugs

Volumn 16, Issue 2, 2002, Pages 77-87

  Hemminki, Akseli ^a   Alvarez, Ronald D ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CISPLATIN; CV 706; CYTOSINE DEAMINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DL 1520E; FLUOROURACIL; INTERLEUKIN 2; NAVELBINE; ONYX 015; PROTEIN P53; THYMIDINE KINASE; TOPOTECAN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CANCER THERAPY; CELL KILLING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; IMMUNE RESPONSE; ONCOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TOXICITY; TRANSCRIPTION REGULATION; TRANSGENE; VIRAL GENE THERAPY;

EID: 0036091358     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200216020-00001     Document Type: Article

References (153)

1. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
2. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
3. A phase I/II study of herpes simplex virus type I thymidine kinase 'suicide' gene therapy for recurrent glioblastoma
4. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses
5. A phase III clinical evaluation of herpes simplex virus type I thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme
6. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
7. Lentiviral vectors: Turning a deadly foe into a therapeutic agent
8. Gene therapy for human cancer: An essay for clinicians
9. An intravenous phase I trial of a replication-competent virus, PV701, in the treatment of patients with advanced solid cancers
10. Reovirus therapy of tumors with activated Ras pathway
11. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
12. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
13. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
14. Nonviral gene therapy: Promises and challenges
15. Update on adenovirus and its vectors
16. Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy
17. Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer
18. Trans-complementation of vector replication versus coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells
19. Fiber knob modifications overcome low, heterogeneous expression of the coxsackie-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells
20. Muscle-specific overexpression of the adenovirus primary receptor CAR overcomes low efficiency of gene transfer to mature skeletal muscle
21. Significant increase of adenovirus infectivity in glioma cell lines by extracellular domain of hCAR
22. Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression
23. Integrin alphavbeta1 is an adenovirus coreceptor
24. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector
25. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse
26. Blood clearance rates of adenovirus type 5 in mice
27. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver
28. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism
29. Selectivity of TAG-72 targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro
30. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches
31. Detection of coxsackie-adenovirus receptor (CAR) immunoreactivity in ovarian tumors of epithelial derivation
32. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector
33. Transduction efficiency of adenoviral vectors in colorectal cancer cells is determined by the presence of the coxsackie adenovirus receptor
34. Coxsackie adenovirus receptor immnohistochemical staining in superficial bladder tumors
35. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures
36. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy
37. Inhibition of the MAPK pathway up-regulates the human coxsackie and adenovirus receptor (CAR) and increases the infectivity of cancer cells with adenovirus
38. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products
39. Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients
40. Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity
41. The promise and potential hazards of adenovirus gene therapy
42. Clinical trials: Gene therapy death prompts review of adenovirus vector
43. A phase I clinical trial of intra-arterial adenovirus p53 (SCH58500) gene therapy for colorectal tumors metastatic to the liver
44. Multi-dose intraperitoneal Rad/p53 (SCH58500) gene replacement combined with chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival
45. Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response
46. Review - The use of immunosuppressive agents to prevent neutralizing antibodies against a transgene product
47. Improvements in gene therapy: Averting the immune response to adenoviral vectors
48. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy
49. A simplified system for generating recombinant adenoviruses
50. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
51. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors
52. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses
53. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
54. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
55. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV- TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients
56. Adenoviral-mediated suicide gene therapy for ovarian cancer
57. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors
58. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial
59. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer
60. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
61. A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients
62. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial
63. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer
64. CT-guided intratumoral gene therapy in non-small-cell lung cancer
65. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
66. Intraprostatic Ad-p53 gene therapy induces apoptosis in locally advanced adenocarcinoma of the prostate
67. A phase I pharmacokinetic study of intravenous (IV) p53 gene therapy with RPR/INGN-201 in patients (pts) with advanced cancer
68. Phase I intraperitoneal p53 gene transfer in ovarian cancer
69. Gene therapy of bladder cancer: Phase I results with Ad5CMV-p53 (RPR/INGN 201)
70. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin
71. Gene therapy for non-small cell lung cancer: A preliminary report of a phase I trial of adenoviral p53 gene replacement
72. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study
73. A phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma
74. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a phase 1 clinical trial
75. Human gene marker/therapy clinical protocols (complete updated listings)
76. Targeted gene delivery by tropism-modified adenoviral vectors
77. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma
78. Targeting of adenoviral vectors through a bispecific single-chain antibody
79. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells
80. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids
81. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM
82. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor
83. Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropism modified adenovirus vector
84. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer
85. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: Evidence for reduced toxicity and enhanced antitumor activity in mice
86. Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors
87. Use of a novel cross-linking method to modify adenovirus tropism
88. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity
89. Genetic targeting of adenoviral vectors
90. Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas
91. Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer
92. Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid
93. An infectivity enhanced adenovirus mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression
94. Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients
95. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer
96. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob
97. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine
98. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
99. Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information
100. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
101. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro
102. Prodrug-activating systems in suicide gene therapy
103. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study
104. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector
105. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial
106. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - A phase 1 study
107. Replicative adenoviruses for cancer therapy
108. The development of conditionally replicative adenoviruses for cancer therapy
109. Conditionally replicative adenoviral vectors for cancer gene therapy
110. Replication-selective adenoviruses as oncolytic agents
111. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
112. New developments in the virus therapy of cancer: A historical review
113. Studies on the use of viruses in the treatment of carcinoma of the cervix
114. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
115. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
116. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
117. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
118. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
119. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015)
120. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
121. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: The importance of the adenoviral E1b-55kD gene
122. Does the antitumor adenovirus ONYX-015/d11520 selectively target cells defective in the p53 pathway?
123. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
124. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
125. Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis
126. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy
127. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
128. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
129. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
130. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
131. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
132. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors
133. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
134. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer
135. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors
136. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule
137. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency
138. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
139. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
140. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial
141. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity
142. Clinical research results with d11520 (Onyx-015), a replication selective adenovirus for the treatment of cancer: What have we learned?
143. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for local recurrence of prostate cancer after definitive radiation therapy
144. Final results of a Phase I study of CV706, a conditionally replication-competent cytolytic adenovirus, for the treatment of locally-recurrent prostate cancer
145. Intra-arterial administration of a replication-selective Adenovirus Ci-1042 (Onyx-015) in patients with colorectal carcinoma metastatic to the liver: Safety, feasibility and biological activity
146. E1B-deleted Adenovirus (d11520) gene therapy for patients with primary and secondary liver tumors
147. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
148. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
149. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)
150. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial